Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("GORE, M. E")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 116

  • Page / 5
Export

Selection :

  • and

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapiesGORE, M. E; LARKING, Jmg.British journal of cancer. 2011, Vol 104, Num 3, pp 399-406, issn 0007-0920, 8 p.Article

Neoadjuvant chemotherapy for locally advanced cervical cancerTIMOTHEADOU, E; GORE, M. E.European journal of cancer (1990). 2003, Vol 39, Num 17, pp 2419-2421, issn 0959-8049, 3 p.Article

Revised U.K. guidelines for the management of cutaneous melanoma 2010MARSDEN, J. R; NEWTON-BISHOP, J. A; PEACH, H et al.British journal of dermatology (1951). 2010, Vol 163, Num 2, pp 238-256, issn 0007-0963, 19 p.Article

A phase II trial of ZD0473 in platinum-pretreated ovarian cancerGORE, M. E; ATKINSON, R. J; THOMAS, H et al.European journal of cancer (1990). 2002, Vol 38, Num 18, pp 2416-2420, issn 0959-8049, 5 p.Article

Staging investigations and the U.K. guidelines for cutaneous melanoma: reply from authorsBISHOP, J. A; CORRIE, P. G; EVANS, J et al.British journal of dermatology (1951). 2002, Vol 147, Num 4, issn 0007-0963, p. 838Article

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesSCHELLENS, J. H. M; HEINRICH, B; CALVERT, H et al.Investigational new drugs. 2002, Vol 20, Num 1, pp 83-93, issn 0167-6997, 11 p.Article

GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha) : A phase I trial in melanomaVAUGHAN, M. M; MOORE, J; RICHES, P. G et al.Annals of oncology. 2000, Vol 11, Num 9, pp 1183-1189, issn 0923-7534Article

A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancerSAVAGE, P; COSTELNA, D; MOORE, J et al.European journal of cancer (1990). 1997, Vol 33, Num 7, pp 1149-1151, issn 0959-8049Article

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease : a pragmatic prognostic indexO'BRIEN, M. E. R; MILAN, S; CUNNINGHAM, D et al.British journal of cancer. 1996, Vol 73, Num 10, pp 1272-1277, issn 0007-0920Article

Chlorambucil for platinum-refractory ovarian cancerTAYLOR, A. E; GORE, M. E.Clinical oncology (Springer. Print). 1994, Vol 6, Num 3, pp 177-178, issn 0936-6555Article

High-dose melphalan for multiple myeloma : long-term follow-up dataCUNNINGHAM, D; PAZ-ARES, L; NORMAN, A et al.Journal of clinical oncology. 1994, Vol 12, Num 4, pp 764-768, issn 0732-183XArticle

Protacted oral etoposide in epithelial ovarian cancer : a phase II study in patients with relapsed or platinum-resistant diseaseSEYMOUR, M. T; MANSI, J. L; GALLAGHER, C. J et al.British journal of cancer. 1994, Vol 69, Num 1, pp 191-195, issn 0007-0920Article

Cisplatin/carboplatin cross-resistance in ovarian cancerGORE, M. E; FRYATT, I; WILTSHAW, E et al.British journal of cancer. 1989, Vol 60, Num 5, pp 767-769, issn 0007-0920Article

Intensive treatment of multiple myeloma and criteria for complete remissionGORE, M. E; SELBY, P. J; ZUIABLE, A et al.Lancet (British edition). 1989, Num 8668, pp 879-882, issn 0140-6736Article

A monoclonal antibody which differentiates between bound and free human secretory componentGORE, M. E; BUNNAGE, H. J; MCILHINNEY, R. A. J et al.European journal of immunology. 1984, Vol 14, Num 4, pp 344-349, issn 0014-2980Article

New approaches to the systemic treatment of melanomaCHOWDHURY, S; VAUGHAN, M. M; GORE, M. E et al.Cancer treatment reviews. 1999, Vol 25, Num 5, pp 259-270, issn 0305-7372Article

Second primary melanomas on treatment with vemurafenib: reply from the authorsFEARFIELD, L; NEWTON-BISHOP, J. A; SINHA, R et al.British journal of dermatology (1951). 2013, Vol 168, Num 4, pp 888-889, issn 0007-0963, 2 p.Article

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensKRASNER, C. N; MCMEEKIN, D. S; CHAN, S et al.British journal of cancer. 2007, Vol 97, Num 12, pp 1618-1624, issn 0007-0920, 7 p.Article

A phase i dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancerGIBBS, D. D; PYLE, L; ALLEN, M et al.British journal of cancer. 2002, Vol 86, Num 9, pp 1379-1384, issn 0007-0920Article

Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancyGREGORY, R. K; HILL, M. E; MOORE, J et al.European journal of cancer (1990). 2000, Vol 36, Num 4, pp 503-507, issn 0959-8049Article

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanomaPALMER, K; MOORE, J; FISHER, C et al.Human gene therapy. 1999, Vol 10, Num 8, pp 1261-1268, issn 1043-0342Article

Delayed haemolytic transfusion reaction caused by anti-M antibody in a patient receiving interleukin-2 and interferon for metastatic renal cell cancerPARRY-JONES, N; GORE, M. E; TAYLOR, J et al.Clinical and laboratory haematology. 1999, Vol 21, Num 6, pp 407-408, issn 0141-9854Article

A matched control study of familial epithelial ovarian cancer : patient characteristics, response to chemotherapy and outcomeCHANG, J; FRYATT, I; PONDER, B et al.Annals of oncology. 1995, Vol 6, Num 1, pp 80-82, issn 0923-7534Article

A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma : clinical data and immunomonitoringDUMMER, R; GORE, M. E; HANCOCK, B. W et al.Cancer. 1995, Vol 75, Num 4, pp 1038-1044, issn 0008-543XArticle

Carcinosarcoma of the ovary : incidence, prognosis, treatment and survival of patientsCHANG, J; SHARPE, J. C; A'HERN, R. P et al.Annals of oncology. 1995, Vol 6, Num 8, pp 755-758, issn 0923-7534Article

  • Page / 5